Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura.Baillieres Clin. Haematol. 1998; 11: 509-514
- Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.N. Engl. J. Med. 1991; 325: 393-397
- Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relapse: frequency, pathogenesis, and meaning.Semin. Hematol. 1997; 34: 134-139
- Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.Blood. 2005; 106: 1932-1937
- Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.Haematologica. 2008; 93: 930-933
- Adjuvant low-dose rituximab and plasma exchange for acquired TTP.Blood. 2019; 134: 1106-1109
- Single-dose versus low-dose rituximab in corticosteroid-resistant or relapsed ITP: a multicenter, randomized, controlled study.Am. J. Hematol. 2022; 97: 440-447
- Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.Br. J. Haematol. 2012; 158: 323-335
- Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.J. Thromb. Haemost. 2017; 15: 312-322
- A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.Blood. 2011; 118: 1746-1753